• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

The recommendations listed in this clinical practice guideline are, whenever possible,
evidence-based. An initial extensive evidence review, which included literature derived from …

Cardiomyopathies are a heterogeneous group of heart muscle diseases and an important
cause of heart failure (HF). Current knowledge on incidence, pathophysiology and natural …

Introduction Chloroquine and hydroxychloroquine are widely used in the long-term
treatment of connective tissue disease and usually considered safe. However, chloroquine …

Background Patients with nonobstructive hypertrophic cardiomyopathy (nHCM) often
experience a high burden of symptoms; however, there are no proven pharmacological …

Kardiomiopatie definiuje się jako strukturalne oraz funkcjonalne nieprawidłowości mięśnia
komór, które nie wynikają z niedokrwienia na skutek choroby wieńcowej czy …

In this scientific statement from the American Heart Association, experts in the field of
cardiomyopathy (heart muscle disease) in children address 2 issues: the most current …

Background—Hypertrophic cardiomyopathy (HCM) is the most common cause of sudden
death in the young, although not all patients eligible for sudden death prevention with an …

Many patients undergoing coronary angiography because of chest pain syndromes,
believed to be indicative of obstructive atherosclerosis of the epicardial coronary arteries …

Objectives: The aims of this study included performing a meta-analysis of the predictive
value of late gadolinium enhancement (LGE) cardiac magnetic resonance (CMR) for …